Monopar Therapeutics Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Note 5 - Stock Incentive Plan (Tables)

Note 5 - Stock Incentive Plan (Tables)

3 Months Ended

Mar. 31, 2025

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

		*Options Outstanding*
		*Number of Shares Subject to Options*				*Weighted-Average Exercise Price*
Balance at December 31, 2024			428,915			$	19.35
Granted⁽¹⁾			216,331				31.45
Forfeited⁽²⁾⁽³⁾			(20,831	)			3.71
Exercised			(4,167	)			3.71
Balance at March 31, 2025			620,248				24.20
Unvested options outstanding expected to vest⁽³⁾			251,035				27.31

Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

Exercise Prices		Number of Shares Subject to Options Outstanding				Weighted-Average Remaining Contractual Term in Years				Number of Shares Subject to Options Fully Vested and Exercisable				Weighted-Average Remaining Contractual Term in Years
$0.00 - $25.00			261,170				5.97				202,433				5.37
$25.01 - $50.00			335,239				7.82				142,943				5.01
$50.01 - $75.00			22,614				4.73				22,612				4.73
$75.01 - $100.00			1,225				4.84				1,225				4.84
			620,248				6.93				369,213				5.19

Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

						*Weighted- Average*
		*Restricted*				*Grant Date*
		*Stock Units*				*Fair Value*
						*per Unit*
Unvested Balance at December 31, 2024			40,739			$	13.92
Granted			120,941				31.70
Vested			(12,316	)			22.76
Forfeited			—				—
Unvested Balance at March 31, 2025			149,364				27.59

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]

		*Three Months Ended March 31,*
		*2025*				*2024*

Stock options granted			216,331				2,000
Weighted-average grant date fair value per share		$	29.17			$	1.25
Fair value of shares vested		$	745,436			$	178,650